HALO Halozyme Therapeutics Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.

Levi & Korsinsky announces it has commenced an investigation of Halozyme Therapeutics, Inc. (NASDAQGS: HALO) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

http://www.zlkdocs.com/HALO-Info-Request-Form-6557

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
22/03/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc: 1 director

A director at Halozyme Therapeutics Inc sold 20,000 shares at 43.726USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

Thanks to a better fundamental star rating, HALOZYME THERAPEUTICS sees...

The independent financial analyst theScreener just awarded an improved star rating to HALOZYME THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date March 18, 2022, the clo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch